相关实验视频

Updated: Jan 8, 2026

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus

Published on: August 25, 2017

用PD-1/PD-L1抑制剂治疗卡波西肉瘤:系统性审查和元分析

Francisco Cezar Aquino de Moraes¹, Michele Kreuz², Pedro Henrique de Souza Wagner³

¹Federal University of Pará, Belém, Pará, Brazil.

Journal of immunotherapy (Hagerstown, Md. : 1997)

|December 15, 2025

概括

PD-1/PD-L1抑制剂对卡波西肉瘤 (KS) 具有显著的抗瘤活性,这是由人类马 herpesvirus 8 (HHV-8) 引起的瘤. 虽然和疲劳等不良事件很常见,但它们通常是可以控制的,为化疗提供了一个有希望的替代方案.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
病毒学病毒学

背景情况:

卡波西肉瘤 (KS) 是一种与人类型疹病毒8 (HHV-8) 相关的血管增殖性瘤.
对于晚期KS的传统化疗,由于毒性和有效性有限,存在挑战.
免疫检查点抑制剂,特别是PD-1/PD-L1抑制剂,代表了一种新的治疗途径,具有潜在的抗瘤益处和改善的安全性.

研究的目的:

在卡波西肉瘤患者中对PD-1/PD-L1抑制剂的疗效和安全性进行元分析.
综合现有的单臂试验数据,提供治疗结果的全面概述.
为了比较免疫疗法的有效性和耐受性与传统的KS治疗.

主要方法:

在主要数据库 (Medline,Embase,Cochrane图书馆,Web of Science) 进行系统的文献搜索.
包括单臂试验,研究卡波西肉瘤的PD-1/PD-L1抑制剂.
结果的统计分析包括客观响应率 (ORR),完整响应率 (CR),疾病控制率 (DCR) 和不良事件 (AE),使用比例和95%置信区间 (CI). 使用I2.2评估异质性.

主要成果:

分析了五项涉及91名患者的研究,之前的治疗包括化疗,放射治疗和干扰素.
综合的客观反应率 (ORR) 为61% (95% CI: 49-72%),完全反应率 (CR) 为17% (95% CI: 8-31%).
疾病控制率 (DCR) 达到91% (95% CI:81-96%). 常见的不良事件包括 (42%),疲劳 (27%) 和关节痛 (14%),这些事件大多是可以控制的.

结论:

PD-1/PD-L1 抑制剂在卡波西肉瘤中表现出显著的抗瘤活性.
免疫疗法方法为高级KS提供了传统化疗的可行替代方案.
虽然不良事件很常见,但它们通常在临床上是可控的,支持在KS治疗中使用这些药物.

关键词:

卡波西肉瘤是卡波西肉瘤的一种.这是一种PD-1/PD-L1抑制剂.有效性有效性有效性.进行元分析.在安全方面,安全是安全的.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV

Published on: September 14, 2010

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...